Matrix metalloproteinases (MMPs) are calcium-dependent zinc containing endopeptidases responsible for the degradation of most of extracellular matrix proteins during organogenesis, growth and normal tissue turnover. MMPs play a role in almost every biological cell process from embryo implantation to cell death and have been implicated in a wide range of diseases including inflammation, arthritis, pulmonary disease, cancer and more.
PerkinElmer’s IVISense™ MMP NIR activatable fluorescence probes (MMPSense®) are designed to evaluate many disease related processes including cancer progression, rheumatoid arthritis, pulmonary disease and more as well as evaluating therapeutic efficacy of potential drug candidates.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
IVISense MMP 645 FAST is excited by 649 nm excitation light, and emits at 666 nm. MMP 645 FAST is a member of a family of activatable fluorescent imaging agents comprising a novel architecture termed F.A.S.T. (Fluorescent Activatable Sensor Technology), that allows for an earlier optimal imaging window of 6-24 hours after injection, facilitating detection of early MMP activity changes, for example in acute models of inflammation or stroke. Including IVISense MMP 645 FAST in careful experimental design allows for multiplexing with other channels and/or imaging times, and so can be paired with other probes to achieve maximum efficiency and flexibility in imaging.
|Fluorescent Agent Type||Activatable|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IVISense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||645 nm|
MMPSense 645 FAST a member of a family of activatable fluorescent imaging agents comprising a novel architecture termed F.A.S.T. (Fluorescent Activatable Sensor Technology), that confers an improved pharmacokinetic profile with earlier imaging time points. This architecture offers higher target specific signal with reduced background while also reducing the optimal imaging time after injection.
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.
Learn about several important best practices, from proper probe selection to study design to imaging technique tips and tricks needed to generate meaningful biological information from your in vivo fluorescence imaging studies.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.